drugset / Trial / NCT02139618

Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage

NCT02139618

RandomizedParallel-groupDouble-blindTreatment

Summary

Treatment of actinic damage has included multiple procedures but to date there is limited scientific evidence to support the preferential use of one of these therapies according to their efficacy, safety and pain tolerance by patients. This study aims to assess the efficacy of methyl aminolevulinate + daylight vs placebo + daylight to treat facial photodamage

Timeline

Start
2014-04
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject methyl aminolevulinate Small molecule 1 g Topical